Berkeley, United States
Renasant Bio, with its slogan "Transforming the Treatment of ADPKD," is making significant strides in the Biotechnology sector. The company is dedicated to developing disease-modifying oral small molecule treatments specifically for autosomal dominant polycystic kidney disease (ADPKD), a leading genetic cause of end-stage renal failure. Their innovative approach focuses on oral small molecule corrector and potentiator programs aimed at rectifying the underlying biology of ADPKD to halt disease progression.
Though the exact founding date and headquarters location are not specified, Renasant Bio recently secured a substantial $54.50M seed investment on 01 July 2025. Key investors in this funding round include notable names like Atlas Venture, 5AM Ventures, OrbiMed, and Qiming Venture Partners USA. This recent influx of capital is a strong testament to the confidence these investors have in the company's potential to significantly impact the treatment landscape for ADPKD.
